// App-Quantinova.ai

839TiP : A phase II clinical trial of radium-223 activity in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status (EXCAAPE)

Researchers

Presenter

  • J.Carles Galceran

Principal Investigators

  • T.Bonfill Abella

  • P.Borrega

  • R.Collado

  • J.Garde

  • M.A.Gonzalez del Alba Baamonde

  • E.Grande Pulido

  • B.Mellado

  • M.J.Mendez Vidal

  • J.M.Piulats Rodriguez

  • R.Morales Barrera

  • E.Gallardo Diaz

  • P.Paredes

  • C.Suarez Rodriguez

  • O.Reig

  • S.Vazquez Estevez

Medical Centers

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Medica Scientia Innovation Research (MedSIR), Barcelona, Spain

  • Parc Tauli University Hospital, Parc Tauli Institute of Research and Innovation I3PT, Barcelona Autonomous University, Sabadell, Spain

  • San Pedro de Alcantara Hospital, Caceres, Spain

  • Son Espases University Hospital, Palma De Mallorca, Spain

  • Ramon y Cajal University Hospital, Madrid, Spain

  • Clinic and Provincial University Hospital, Barcelona, Spain

  • Reina Sofia University Hospital, Cordoba, Spain

  • Catalan Institute of Oncology, Badalona, Spain

  • Lucus Augusti University Hospital, Lugo, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved